Id: | acc0519 |
Group: | 1sens |
Protein: | beta-catenin |
Gene Symbol: | CTNNB1 |
Protein Id: | P35222 |
Protein Name: | CTNB1_HUMAN |
PTM: | phosphorylation |
Site: | Tyr654 |
Site Sequence: | HSRNEGVATYAAAVLFRMSED |
Disease Category: | Cancer |
Disease: | Thyroid Cancer |
Disease Subtype: | anaplastic thyroid carcinoma |
Disease Cellline: | SW1736 |
Disease Info: | |
Drug: | I131 |
Drug Info: | "Iodine-131 (I-131) is a radioactive isotope used as a therapeutic agent for hyperthyroidism and thyroid cancer, functioning by emitting beta radiation to selectively destroy overactive thyroid cells or malignant thyroid tissue, with a physical half-life of approximately 8 days and administered orally or intravenously as a radiopharmaceutical. " |
Effect: | inhibit |
Effect Info: | "ATRA treatment reduced the phosphorylation of beta-catenin (Ser45 and Y654) and GSK-3beta (Ser9), thereby enhancing the sensitivity of undifferentiated thyroid cancer to isotopic therapy." |
Note: | Non-conventional drugs |
Score: | 4.5 |
Pubmed(PMID): | 29344218 |
Sentence Index: | 29344218_0 |
Sentence: | ATRA increases iodine uptake and inhibits the proliferation and invasiveness of human anaplastic thyroid carcinoma SW1736 cells: Involvement of beta-catenin phosphorylation inhibition. |
Sequence & Structure:
MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 2 | Withdrawn | colorectal adenocarcinoma | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 2 | Recruiting | cirrhosis of liver | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | acute myeloid leukemia | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | chronic myelogenous leukemia | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Terminated | neoplasm | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | pancreatic carcinoma | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | pancreatic adenocarcinoma | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | Malignant Pancreatic Neoplasm | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
CTNNB1-Ser179 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -0.962 | ||||
COAD | 0.455 | ||||
HGSC | 1.973 | ||||
ccRCC | -1.319 | ||||
GBM | -0.972 | ||||
HNSC | 0.229 | ||||
LUAD | |||||
LUSC | |||||
non_ccRCC | -0.072 | ||||
PDAC | 0.409 | ||||
UCEC | 0.257 |
CTNNB1-Ser191 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -1.014 | ||||
COAD | -0.344 | ||||
HGSC | 0.922 | ||||
ccRCC | -0.101 | ||||
GBM | 0.311 | ||||
HNSC | 0.693 | ||||
LUAD | 0.681 | ||||
LUSC | 0.136 | ||||
non_ccRCC | 1.119 | ||||
PDAC | -2.383 | ||||
UCEC | -0.021 |
CTNNB1-Ser222 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | -0.549 | ||||
HNSC | |||||
LUAD | -0.77 | ||||
LUSC | 1.445 | ||||
non_ccRCC | |||||
PDAC | |||||
UCEC | -0.126 |
CTNNB1-Ser33 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | -1.746 | ||||
ccRCC | 0.213 | ||||
GBM | 1.104 | ||||
HNSC | -0.324 | ||||
LUAD | -0.011 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.764 |
CTNNB1-Ser37 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | -0.655 | ||||
GBM | 1.477 | ||||
HNSC | -0.252 | ||||
LUAD | -0.57 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
CTNNB1-Ser45 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -0.184 | ||||
HGSC | -1.332 | ||||
ccRCC | |||||
GBM | 0.613 | ||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.904 |
CTNNB1-Ser552 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -1.793 | ||||
COAD | -0.07 | ||||
HGSC | 0.724 | ||||
ccRCC | 1.879 | ||||
GBM | -0.666 | ||||
HNSC | 0.383 | ||||
LUAD | 0.034 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | -0.172 | ||||
UCEC | -0.318 |
CTNNB1-Ser675 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -0.341 | ||||
COAD | -0.152 | ||||
HGSC | 2.444 | ||||
ccRCC | -0.185 | ||||
GBM | 0.26 | ||||
HNSC | 0.094 | ||||
LUAD | -0.329 | ||||
LUSC | 0.129 | ||||
non_ccRCC | -0.617 | ||||
PDAC | -1.752 | ||||
UCEC | 0.448 |
CTNNB1-Thr217 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | 0.319 | ||||
HNSC | 0.802 | ||||
LUAD | -1.121 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
CTNNB1-Thr40 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | -0.707 | ||||
ccRCC | |||||
GBM | 0.707 | ||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
CTNNB1-Thr41 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | 0.385 | ||||
ccRCC | |||||
GBM | 0.75 | ||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | -1.135 |
CTNNB1-Thr551 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | 0.362 | ||||
HGSC | -1.588 | ||||
ccRCC | |||||
GBM | |||||
HNSC | 0.735 | ||||
LUAD | 0.046 | ||||
LUSC | 1.147 | ||||
non_ccRCC | |||||
PDAC | |||||
UCEC | -0.701 |
CTNNB1-Thr556 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -0.707 | ||||
HGSC | 0.707 | ||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
CTNNB1-Tyr30 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | 0.707 | ||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | -0.707 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
CTNNB1-Tyr716 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.807 |
HGSC | 1.119 |
ccRCC | |
GBM | -0.312 |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
Y | 654 | P | Intestinal cancer | Phosphorylation | 21307168 |
Y | 654 | U | Idiopathic pulmonary fibrosis | Phosphorylation | 19104148 |
Y | 654 | U | Nasopharyngeal carcinoma | Phosphorylation | 37496925 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.